Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.


BioSante shares up after cancer drug meets goals

BioSante Pharmaceuticals Inc. said Thursday its potential pancreatic cancer treatment met key goals in a midstage study.

The company’s stock surged 32 cents, or 16 percent, to $2.35 in premarket trading.

The company said a newly published study showed the vaccine increased the median survival rate of patients by more than 25 percent to 24.8 months. The results were published in the February issue of the Annals of Surgery and involved 60 patients undergoing treatment at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore. Get the full story »

BioSante to sell $18M of securities to investors

Lincolnshire-based BioSante Pharmaceuticals has signed a $18 million deal with several investors to sell 10.6 million shares of its common stock. Get the full story »

BioSante added to Russell 3000

BioSante Pharmaceuticals Inc. said today it has been added to the broad-market Russell 3000 Index as part of Russell Investments’ recent reconstitution of its comprehensive set of U.S. and global equity indexes after market close Friday. Get the full story »